Evecxia Therapeutics

Evecxia Therapeutics is the first company dedicated to realizing the therapeutic potential of 5-hydroxytryptophan (5-HTP) for the treatment of mental illness. Mental illness negatively impacts all aspects of life – from internal emotional states, to work and scholastic performance, to relationships with family and friends. Evecxia Therapeutics' mission is to help people suffering from disabling mental illness, and not treated adequately by current therapies, to lead fuller, more meaningful lives.

Round: Series B, USD

Basking Biosciences

Basking Biosciences, Inc., is developing the first reversible thrombolytic therapy for Acute Ischemic Stroke (AIS). Dr. Bruce Sullenger of Duke University and Dr. Shahid Nimjee, of Ohio State University founded the company to commercialize aptamers with high affinity and specificity against proteins involved in coagulation and hemostasis.

Round: Series A, USD

Mebias Discovery

MEBIAS, an emerging leader in the field of pathway-selective G-protein coupled receptor (GPCR) drug discovery, was founded in January 2016 by 3 highly experienced drug discovery scientists, formerly of Johnson & Johnson and Merck. The ability to accurately design GPCR-targeting medicines with well-established mechanisms that avoid specific side effects within a therapeutic index — known as pathway-selective drug discovery — presents a unique opportunity with lower risk than utilizing traditional techniques to explore new, non-validated mechanisms. Initial areas of focus for MEBIAS are Neuroscience/Pain, Metabolic, Gastroparesis, and Inflammatory-related disorders.

Round: Series B, USD

AcuraStem

AcuraStem is employing cutting-edge technology in its efforts to find treatments and cures for neurodegenerative diseases (NDDs). AcuraStem's best-in-class technology platform consists of complex cellular models from ALS patient cells and sophisticated assays which permit AcuraStem's scientists to model patient tissues in the laboratory. Using this ground-breaking technology, they can screen small molecule or gene targeting libraries to discover the most efficacious therapeutic opportunities.AcuraStem's iNeuroRx® platform is a breakthrough disease modeling platform, leveraging neurons derived from patients and advanced machine learning to discover therapeutic opportunities that rescue healthy motor neurons in those affected by neurodegenerative diseases, like ALS and FTD (frontotemporal dementia).

Round: Series A, USD

VersaPeutics

VersaPeutics is a privately held specialty pharmaceutical company focusing on discovering and advancing novel therapeutic approaches for Alzheimer's disease. As the proprietary scientific platform of VersaPeutics is built upon novel approaches to regulate the Wnt/planar cell polarity (PCP) signaling pathway, additional therapeutic areas within our focus include spinal cord injury, neuropathic pain, and oncology.

Round: Series B, USD

GenHouse Bio

Genhouse is focusing on the development of the world's leading small molecule anti-tumor drugs. The company's management has many years of experience in corporate management, new drug research and development, and clinical medicine research, and they are committed to breaking through the target of "un-druggable drugs" and focusing on original innovation.

Round: Series A+, RMB